The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

SensiFAST™ Genotyping Kit Exceed the Limit

Wednesday, November 28, 2012

SensiFAST™ Genotyping Kit Exceed the Limit07:00 EST Wednesday, November 28, 2012 CINCINNATI (Business Wire) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of SensiFAST Genotyping Kit, which has been specifically developed for the important field of genotyping. Bioline's SensiFAST Genotyping Kit has been developed for fast, precise, and highly reproducible genotyping of sequence variants, including loci with type IV SNPs. With outstanding allele clustering, the SensiFAST Genotyping Kit gives exceptional confidence in genotype calling with probe-based real-time PCR SNP detection applications. The kit has been validated on all commonly used instruments and features fast protocol times, making it ideal for high-throughput workflows. Marco Calzavara, President of Bioline commented, "I am delighted to announce the release of another new research tool as part of the SensiFAST family, our rapidly expanding real-time PCR range. Bioline is dedicated to increasing the applications of our industry-leading real-time PCR portfolio tools. The SensiFAST Genotyping Kit will enable researchers to cost-effectively scan DNA from a variety of biological samples to detect the smallest genetic variations among samples.” Richard L. Eberly, President of Meridian Life Science, Inc., stated, “The release of the SensiFAST Genotyping Kit is part of a new generation of products to advance the rapidly expanding portfolio of highly specialized molecular biology reagents from Bioline. We remain committed to our life science customers to bring innovation and quality products to the research lab, clinical diagnostic laboratories, and biotechnology companies.” ABOUT MERIDIAN BIOSCIENCE, INC.Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian's diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, veterinary testing centers, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company's shares are traded through NASDAQ's Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com. ADDITONAL INFORMATIONFor more information about Bioline, please visit www.bioline.comFor more information about Meridian Life Science, Inc., please visit www.meridianlifescience.comFor more information about Meridian Bioscience, Inc., please visit www.meridianbioscience.comRichard L. Eberly, rick.eberly@meridianbioscience.com Meridian Bioscience, Inc.Richard L. Eberly, 513-271-3700